A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients

Exclusion Criteria

• •Currently receiving treatment in another investigational device or drug study or participation in non-interventional studies
• •Current treatment with etelcalcetide (Parsabiv©) or treatment with etelcalcetide within 3 months prior to study inclusion
• •Patient has known sensitivity to any of the products or components of Parsabiv©
• •Patient has received a parathyroidectomy
• •Parathyroidectomy planned or expected during the study period
• •Elective kidney transplant scheduled during the study period
• •Therapy with bisphosphonates within the past 12 months
• •Therapy with denosumab within the past 6 months
• •Antacids containing aluminum, calcium, magnesium or bicarbonate
• •Patient has a history of symptomatic ventricular arrhythmias or Torsades de Pointes
• •Patient has a history of myocardial infarction, coronary angioplasty, or coronary arterial bypass grafting within the past 6 months prior to screening.
• •Pregnant or nursing (lactating) women